Redwood City, Calif. & Boston In a significant development in the biotechnology sector, Adicet Bio, Inc. (Nasdaq: ACET), a clinical-stage biotechnology company specializing in the development of allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, has announced the acceptance of an abstract for presentation at the esteemed American Society of Gene & Cell Therapy (ASGCT) 28th Annual Meeting. This event, one of the most anticipated gatherings in gene and cell therapy, is scheduled to take place from May 13-17, 2025, in New Orleans, Louisiana.Presentation Details Highlighting ADI-270:
Adicet Bio s oral presentation will focus on the preclinical data related to ADI-270, which could signal significant progress in developing therapies for challenging conditions. The presentation aims to showcase innovative approaches and technical prowess in harnessing gamma delta T cell therapies to combat autoimmune diseases and cancer.
Comments